UCL Discovery Stage
UCL home » Library Services » Electronic resources » UCL Discovery Stage

Non–vitamin K oral anticoagulants in hypertrophic cardiomyopathy patients undergoing catheter ablation of atrial fibrillation

Creta, A; Hunter, RJ; Earley, MJ; Finlay, M; Dhinoja, M; Sporton, S; Chow, A; ... Providência, R; + view all (2020) Non–vitamin K oral anticoagulants in hypertrophic cardiomyopathy patients undergoing catheter ablation of atrial fibrillation. Journal of Cardiovascular Electrophysiology , 31 (10) pp. 2626-2631. 10.1111/jce.14659. Green open access

[thumbnail of Lambiase_HCM NOAC 06 05 2020-2.pdf]
Preview
Text
Lambiase_HCM NOAC 06 05 2020-2.pdf - Accepted Version

Download (488kB) | Preview

Abstract

INTRODUCTION: Patients with hypertrophic cardiomyopathy (HCM) and atrial fibrillation (AF) require chronic anticoagulation due to a high thromboembolic risk. Evidence supporting use of non-vitamin K oral anticoagulants (NOACs) in patients with HCM remains sparse, and there are no data regarding the use of NOACs in HCM patients undergoing catheter ablation of AF. METHODS: Observational non-randomised study in 4 European Centres. We aimed to investigate the safety and efficacy of NOACs compared with vitamin-K antagonists (VKAs) in patients with HCM undergoing catheter ablation for AF. RESULTS: One hundred thirty-seven HCM patients (mean age 55.0±13.4, 29.1% female) underwent 230 catheter ablations for AF (1.7±1.0 per patient). A total of 55 patients (39.4%) underwent 70 procedures (30.4%) on NOAC, while the remaining were on VKA. Warfarin (97.6%) and rivaroxaban (56.4%) were the most frequently used agents in the respective groups. No procedure-related deaths were reported. We observed no significant difference in the rate of thromboembolism (VKA 0.6%; NOAC 0%; p=1.0) or minor bleeding (VKA 0.6%; NOAC 1.4%; p=0.54). There was a non-significant trend towards a lower incidence of major bleeding (VKA 6.9%; NOAC 1.4%; p=0.09). CONCLUSION: These preliminary data suggest that NOACs are at least as safe and effective as VKAs in patients with HCM undergoing catheter ablation for AF. This article is protected by copyright. All rights reserved.

Type: Article
Title: Non–vitamin K oral anticoagulants in hypertrophic cardiomyopathy patients undergoing catheter ablation of atrial fibrillation
Location: United States
Open access status: An open access version is available from UCL Discovery
DOI: 10.1111/jce.14659
Publisher version: https://doi.org/10.1111/jce.14659
Language: English
Additional information: This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions.
Keywords: atrial fibrillation, catheter ablation, hypertrophic cardiomyopathy, non-vitamin K oral anticoagulants, warfarin
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute of Cardiovascular Science
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute of Cardiovascular Science > Clinical Science
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute of Health Informatics
URI: https://discovery-pp.ucl.ac.uk/id/eprint/10105830
Downloads since deposit
13,604Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item